dsm-firmenich proposes Richard Ridinger as new chairman as Thomas Leysen steps down

NETHERLANDS – Thomas Leysen, dsm-firmenich’s chair of the board of directors, has decided to retire once the company’s shareholders elect his successor.

The board has unanimously proposed Richard Ridinger, currently an independent director of dsm-firmenich, as his successor.

Shareholders will be asked to approve his appointment at an Extraordinary General Shareholders Meeting on 19 October 2026.

Ridinger brings extensive executive and board-level experience in global businesses across pharmaceuticals, home and personal care, and nutrition and health.

The company praised his deep understanding of the company, positioning him well to succeed Leysen. The company said he will provide continuity to execute its strategy and create long-term value for shareholders and other stakeholders.

Since the formation of the company, a result of the merger between Royal DSM and Firmenich in 2023, Leysen has provided guidance through a period of significant change and challenging market conditions.

The board thanked him for his leadership, adding that he has been ‘instrumental’ in positioning the company for its next growth phase.

Leysen commented: “With dsm-firmenich now fully operating as one company, the portfolio tuning nearing completion with the closing of the Animal Nutrition & Health sale foreseen later this year, the executive committee rejuvenated and the margin improvement program well underway, it is an opportune moment to hand over to a new chair”.

“Richard has all the requisite experience to help bring dsm-firmenich to the next level. It has been a pleasure and an honour to chair the board during the formative stages of this unique company.”

The proposal comes after the company reported better-than-expected second-quarter results, with like-for-like sales growth accelerating to 6% and adjusted EBITDA beating market consensus by 3%. 

According to the company, performance was driven by its Taste, Texture & Health division, which grew 6%, and Perfumery & Beauty, which expanded 7%, while Health, Nutrition & Care delivered steady 4% growth. 

Management noted particularly strong June trading as customer sentiment improved following the easing of Middle East concerns.

Second-quarter adjusted EBITDA reached €466 million (US$534 million), beating Bloomberg consensus of €452 million and Barclays’ estimate of €457 million. 

To receive our email newsletters with the latest news and insights from Africa, the Middle East and around the world, SUBSCRIBE HERE.